Literature DB >> 14709595

Rescue of a human mRNA splicing defect by the plant cytokinin kinetin.

Susan A Slaugenhaupt1, James Mull, Maire Leyne, Math P Cuajungco, Sandra P Gill, Matthew M Hims, Fabiola Quintero, Felicia B Axelrod, James F Gusella.   

Abstract

The defective splicing of pre-mRNA is a major cause of human disease. Exon skipping is a common result of splice mutations and has been reported in a wide variety of genetic disorders, yet the underlying mechanism is poorly understood. Often, such mutations are incompletely penetrant, and low levels of normal transcript and protein are maintained. Familial dysautonomia (FD) is caused by mutations in IKBKAP, and all cases described to date involve an intron 20 mutation that results in a unique pattern of tissue-specific exon skipping. Accurate splicing of the mutant IKBKAP allele is particularly inefficient in the nervous system. Here we show that treatment with the plant cytokinin kinetin alters splicing of IKBKAP. Kinetin significantly increases inclusion of exon 20 from the endogenous gene, as well as from an IKBKAP minigene. By contrast the drug does not enhance inclusion of alternatively spliced exon 31 in MYO5A. Benzyladenine, the most closely related cytokinin, showed a similar but less dramatic effect. Our findings reveal a remarkable impact on splicing fidelity by these small molecules, which therefore provide new tools for the dissection of mechanisms controlling tissue-specific pre-mRNA splicing. Further, kinetin should be explored as a treatment for increasing the level of normal IKAP in FD, and for other splicing disorders that may share a similar mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14709595     DOI: 10.1093/hmg/ddh046

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  56 in total

Review 1.  Cellular reprogramming: recent advances in modeling neurological diseases.

Authors:  Guo-Li Ming; Oliver Brüstle; Alysson Muotri; Lorenz Studer; Marius Wernig; Kimberly M Christian
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

Review 2.  Mechanisms of disease in hereditary sensory and autonomic neuropathies.

Authors:  Annelies Rotthier; Jonathan Baets; Vincent Timmerman; Katrien Janssens
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

3.  Anti-ageing strategies: prevention or therapy? Showing ageing from within.

Authors:  Suresh I S Rattan
Journal:  EMBO Rep       Date:  2005-07       Impact factor: 8.807

Review 4.  Better days are coming for Riley-Day patients.

Authors:  F C Luft
Journal:  J Mol Med (Berl)       Date:  2006-12-22       Impact factor: 4.599

Review 5.  Hereditary Sensory and Autonomic Neuropathies: Adding More to the Classification.

Authors:  Coreen Schwartzlow; Mohamed Kazamel
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-20       Impact factor: 5.081

6.  Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia.

Authors:  Matthew M Hims; El Chérif Ibrahim; Maire Leyne; James Mull; Lijuan Liu; Conxi Lazaro; Ranjit S Shetty; Sandra Gill; James F Gusella; Robin Reed; Susan A Slaugenhaupt
Journal:  J Mol Med (Berl)       Date:  2007-01-06       Impact factor: 4.599

Review 7.  Induced pluripotent stem cells: a new tool to confront the challenge of neuropsychiatric disorders.

Authors:  Flora M Vaccarino; Hanna E Stevens; Arif Kocabas; Dean Palejev; Anna Szekely; Elena L Grigorenko; Sherman Weissman
Journal:  Neuropharmacology       Date:  2011-03-01       Impact factor: 5.250

8.  Clinical neuro-ophthalmic findings in familial dysautonomia.

Authors:  Carlos E Mendoza-Santiesteban; Thomas R Hedges; Lucy Norcliffe-Kaufmann; Floyd Warren; Shantan Reddy; Felicia B Axelrod; Horacio Kaufmann
Journal:  J Neuroophthalmol       Date:  2012-03       Impact factor: 3.042

Review 9.  The molecular basis of familial dysautonomia: overview, new discoveries and implications for directed therapies.

Authors:  Berish Y Rubin; Sylvia L Anderson
Journal:  Neuromolecular Med       Date:  2007-11-06       Impact factor: 3.843

10.  The experimental chemotherapeutic N6-furfuryladenosine (kinetin-riboside) induces rapid ATP depletion, genotoxic stress, and CDKN1A(p21) upregulation in human cancer cell lines.

Authors:  Christopher M Cabello; Warner B Bair; Stephanie Ley; Sarah D Lamore; Sara Azimian; Georg T Wondrak
Journal:  Biochem Pharmacol       Date:  2008-12-24       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.